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Objective: To carry out a meta-analysis designed to compare the discriminant capacities of American
College of Rheumatology 50% (ACR50) with 20% (ACR20) responses in clinical trials on rheumatoid
arthritis reported after 1997 and to analyse whether ACR50 can be as informative as ACR20 in
distinguishing active from control treatments in more recent trials.
Methods: Clinical trials on rheumatoid arthritis reported since 1997 were identified, which included
aggressive combinations of disease-modifying antirheumatic drugs and glucocorticoids, as well as
powerful new agents—leflunomide, etanercept, infliximab, anakinra, adalimumab, abatacept, tacrolimus
and rituximab. A meta-analysis of ACR20 compared with ACR50 responses for 21 clinical trials was
carried out on differences in proportions of responders for active and control treatments and
corresponding odds ratios (ORs).
Results: In all but one clinical trial on rheumatoid arthritis published since 1997 with data available on
ACR20 and ACR50, more than 50% of patients who were ACR20 responders among those randomised to
active treatment were also ACR50 responders. This phenomenon was seen for control groups in 38% of
trials, many of which included treatment with methotrexate. A meta-analysis of the clinical trials indicated
a slight advantage to ACR50 for quantifying treatment comparisons, not significant for differences in
proportions but significant for ORs.
Conclusion: ACR20 and ACR50 seem to be similar in distinguishing active from control treatments in
clinical trials on rheumatoid arthritis reported since 1997. As ACR50 represents a considerably stronger
clinical response, ACR50 may be a preferred end point for contemporary clinical trials on rheumatoid
arthritis.
T
he American College of Rheumatology (ACR) core
dataset1–3 has been a major advance in randomised
controlled clinical trials on rheumatoid arthritis.
Improvement criteria have been established as 20%, 50%
and 70% responses at end point compared with baseline, and
termed ACR20, ACR50 and ACR70, requiring improvement in
both swollen and tender joint counts, as well as three of the
other five core dataset measures.4 In a 1998 report, ACR20
responses were found to have greater discriminant capacity
to distinguish active from control treatment than ACR50 or
ACR70 responses.5
Although ACR20 responses may have significant capacities
to distinguish active from control treatment, such levels
generally do not represent an optimal clinical improvement.6
Indeed, the reported superiority of ACR20 compared with
ACR50 or ACR705 suggests that most treatments for
rheumatoid arthritis reported before 1998 had limited
efficacies, albeit statistically significantly greater than seen
for placebo or control treatment. In many chronic diseases,
such as hypertension or hyperlipidaemia, clinicians seek
improvement at .20% levels.
Since the 1998 report, more aggressive treatment strategies
have been introduced, including earlier use of disease-modify-
ing antirheumatic drugs (DMARDs),7 8 with methotrexate as an
‘‘anchor’’ DMARD, often in combinations in a preventive
strategy9 10 with new DMARDs and biological agents. Reports
of clinical trials on methotrexate in combination with other
DMARDs,11–13 and new agents such as monotherapy or in
combination with methotrexate or other DMARDs, including
leflunomide,14 15 etanercept,16 17 infliximab,18 19 anakinra,20 21
adalimumab,22 23 tacrolimus,24 abatacept25 and rituximab,26
indicate higher levels of both ACR20 and ACR50 responses
than were seen in clinical trials included in the 1998 analysis.5
These findings raised consideration of a reassessment of
ACR50 versus ACR20 as an end point in contemporary
clinical trials on rheumatoid arthritis. Therefore, we identi-
fied all 21 clinical trials published between 1997 and 2004 in
which data were available on both ACR20 and ACR50
responses for comparisons of active with control treatment.
In this report, we present two meta-analyses to compare
ACR20 with ACR50 responses, one for differences between
treatments in the proportions of responders and the other for
odds ratios (ORs).
METHODS
Reports of clinical trials on rheumatoid arthritis published
since 1997 were reviewed to evaluate responses to combina-
tion therapies,11–13 leflunomide,14 27–30 etanercept,16 31–33 inflix-
imab,19 34 adalimumab,23 35 36 anakinra,21 tacrolimus,24 37
abatacept25 and rituximab.26 Trials were included only if data
Abbreviations: ACR20, American College of Rheumatology 20%
response criteria; ACR50, American College of Rheumatology 50%
response criteria; DMARD, disease-modifying antirheumatic drug
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on the proportion of patients who met both ACR20 and
ACR50 response criteria with each treatment were reported.
Therefore, published reports of several important clinical
trials38–40 could not be included. Only one published report for
each clinical trial was included. If more than one report was
available, the report with a period of observation closest to
52 weeks was chosen. Overall, 21 trials were included in the
analyses, with the primary treatment comparisons illustrated
in table 1.
The proportions of patients who met ACR20 or ACR50
response criteria were identified for each treatment. A meta-
analysis of the clinical trials was carried out to compare
ACR20 and ACR50 as criteria for assessing active versus
control treatments for change from baseline to end point.
(The term ‘‘control’’ rather than ‘‘placebo’’ is used, as
patients generally took a non-steroidal anti-inflammatory
drug and or glucocorticoid, as well as possibly methotrexate,
albeit after selection for incomplete responses to methotrex-
ate.)
The term ‘‘meta-analysis’’ is used to describe an integrated
quantitative comparison of the findings of many clinical trials
in one analysis. This approach to meta-analysis differed from
most common meta-analyses of clinical trials, which could be
directed to analyse the efficacy of active versus control
treatments. Our meta-analysis was directed to compare two
outcome criteria for their discriminant capacities to detect
differences between active and control treatments, as
reported in the medical literature.
Meta-analyses were carried out for two types of compar-
isons: differences between active and control treatments in
proportions responding, and in ORs for proportions respond-
ing. The extent to which the difference between treatments
for the proportion of patients who met ACR50 was larger
than the corresponding difference in the proportion who met
ACR20 was described for each study by the corresponding
‘‘difference of differences’’ (ACR502ACR20). If more than
one treatment comparison was reported, the comparison
with the most significant difference in differences versus zero
(ie, smallest two-sided p value) was included in the analyses.
This comparison was not the primary comparison for four
clinical trials, as indicated in table 1, as differences between
ACR50 and ACR20 (independent of the level of significance
of the corresponding treatment differences) were more
significant for the comparison that was analysed. The
significance of the extent to which one of the two end points
consistently had larger differences between treatments for
responding proportions was evaluated across studies, using
the Wilcoxon signed ranks test on the respective differences
of differences. A Hodges–Lehmann 95% confidence interval
(CI) was used to describe the magnitude of the median
difference between end points in proportions responding
across studies.41
Table 1 Data for the main treatment comparisons of interest
Clinical trial % ACR20 % ACR50
% ACR20 who are
ACR50
Study no in






p value Exp Comp
Not in figure 3 CSSRD Felson5 DPen, GST, MTX 40 8 9 0 22 0
1 COBRA Boers11 MTX+SSZ+PRED v SSZ 72 49 0.006 49 27 0.007 68 55
2 FinRACo Mottonen12 MTX+SSZ+HCQ+PRED v
SSZ
78 84 NS 71 58 Not shown 91 69
3 Smolen14 LEF v PBO 55 29 ,0.001 33 14 0.002 60 48
SSZ v PBO 56 29 ,0.001 30 14 0.003 54 48
4 Weinblatt31 ETAN+MTX v PBO+MTX 71 27 ,0.001 39 3 ,0.001 55 11
5 Moreland16 ETAN v PBO 59 11 ,0.001 40 5 ,0.01 68 45
6 ULTRA Strand27 LEF v PBO 52 26 ,0.001 34 8 ,0.001 65 31
LEF v MTX 52 46 Not shown 34 23 Not shown 65 50
7 ATTRACT Lipsky19 INFL+MTX v PBO+MTX 59 17 ,0.001 39 8 ,0.001 66 47
8 Scott29 LEF v SSZ 67 69 NS 42 39 NS 63 57





78 60 0.05 55 40 Not shown 71 67
MTX+HCQ+SSZ v
MTX+SSZ
78 49 0.002 55 29 Not shown 71 59
11 Furst24 TAC v PBO 34 16 ,0.05 17 1 ,0.05 50 06
12 ERA (F/U) Genovese32 ETAN v MTX 72 59 0.005 49 42 NS 68 71
13 Cohen21 ANAK+MTX v PBO+MTX 42 23 0.018 24 4 0.003 57 17
14 ARMADA Weinblatt23 ADA+MTX v PBO+MTX 67 15 ,0.001 55 8 ,0.001 82 53
15 STAR Furst35 ADA+DMARD v
PBO+DMARD
53 35 ,0.001 29 11 ,0.001 55 31
16 Kremer25 ABAT+MTX v PBO+MTX 60 35 ,0.001 37 12 ,0.001 62 34
17 Yocum37 TAC v PBO 32 13 ,0.001 12 5 0.02 38 38
18 Keystone36 ADA+MTX v PBO+MTX 59 24 ,0.001 42 10 ,0.001 71 42
19 St Clair34 INFL+MTX v PBO+MTX 62 54 0.028 46 32 ,0.001 74 59
20 TEMPO Klareskog33 ETAN+MTX v ETAN v MTX 85 75 0.009 69 43 ,0.001 81 57
21 Edwards26 RTX+MTX v MTX 73 38 0.003 43 13 0.005 59 34
RTX+CYCLO v MTX 76 38 0.001 41 13 0.005 54 34
RTX+CYCLO v RTX+MTX 76 73 Not shown 41 43 Not shown 54 56
ABAT, abatacept; ACR, American College of Rheumatology; ADA, adalimumab; ANAK, anakinra; ARMADA, Anti-TNF Research Study Program of the
Monoclonal Antibody Adalimumab (D2E7) in Rheumatoid Arthritis; ATTRACT, Anti-TNF Trial in Rheumatoid Arthritis with Concomitant Therapy; COBRA,
Combinatietherapie Bij Reumatoide Artritis; Comp, comparative; 3 CSSRD, Cooperative Systematic Studies of Rheumatic Diseases; CYCLO, cyclosporine; ERA,
early rheumatoid arthritis; ETAN, etanercept; Exp, experiment; DMARD, disease-modifying antirheumatic drug; DPen, D-penicillamine; FinRACo, Finnish
Rheumatoid Arthritis Cooperative Trial; FU, follow-up study; GST, gold sodium thiomalate; HCQ, hydroxychloroquine; INFL, infliximab; LEF, leflunomide; MTX,
methotrexate; PBO, placebo; PRED, prednisone; RTX, rituximab; STAR, Safety Trial of Adalimumab in Rheumatoid Arthritis; SSZ, sulphasalazine; TAC, tacrolimus;
TEMPO, Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes; ULTRA, Utilisation of leflunomide for the treatment of rheumatoid arthritis.
Table 1 presents data for the main treatment comparisons of interest in each study. Figures 1 and 2 present results for treatment comparisons with the most
significant differences between ACR20 and ACR50 for treatment differences and odds ratios, respectively. For study 3,14 these comparisons are not the same.
For studies 3,14 6,27 1013 and 2126, the comparisons shown in table 1 are not the same as in figs 1 and/or 2 or both.
ACR20 and ACR50 in clinical trials after 1997 1603
www.annrheumdis.com
ORs for the comparisons between active and control
treatments were also analysed from the proportions of
patients responding at ACR50 and ACR20 levels. The ratios
of these two ORs were analysed to compare the end points for
each study. Studies with more than one treatment compar-
ison were represented by the ratio of ORs for which the
logarithm was most significantly different from zero (ie,
smallest two-sided p value). The significance of the extent to
which larger ORs were obtained for treatment comparisons
according to one of the two end points was evaluated using
the Wilcoxon signed ranks test on the respective logarithms
of the ratios of ORs. The anti-logarithms of the corresponding
Hodges–Lehmann 95% CI were used to describe the
magnitude of the median ratio of ORs across studies.41
RESULTS
An initial review was conducted of clinical trials included in
the 1998 report, which indicated superior discrimination
between active and control treatment according to compar-
ison of ACR20 with ACR50.5 Data on the primary treatment
comparisons of interest in each trial are shown in table 1.
Table 1 also indicates the four trials in which the comparison
of ACR20 with ACR50 shown in the figures differed from the
primary comparison, as these trials were more significant for
ACR20 versus ACR50. Results from the three trials conducted
by the Cooperative Systematic Studies of the Rheumatic
Diseases indicated ACR20 response in 40% of patients,
consisting of 31% of patients with ACR20 but no ACR50
response and only 9% with ACR50 responses. Therefore,
almost 75% of the patients who responded at the ACR20 level
did not respond at the ACR50 level.
Analyses of more recent clinical trials on combination
therapies suggest that most patients who met ACR20 also
met ACR50 response criteria. In the trial conducted by Boers
et al,11 72% of patients who received glucocorticoids and triple
therapy met ACR20 criteria and 49% met ACR50 criteria at
1 year. Therefore, 68% of ACR20 responders were also ACR50
responders. Similarly, in the study by Möttönen et al,12 78% of
patients receiving combination therapy met ACR20 and 71%
met ACR50 criteria; 91% of ACR20 responders were also
ACR50 responders, the highest proportion of ACR20 respon-
ders who were also ACR50 responders of any trial (including
those with biological agents) published to date.
In all the other clinical trials except one,37 more than 50%
(51–82%) of patients who received active treatment and met
ACR20 criteria also met ACR50 criteria. Furthermore, in 8 of
the 21 studies (38%), more than 50% of patients who met
ACR20 criteria in the control groups of the primary treatment
comparisons also met ACR50 criteria, possibly partly owing to
treatment of patients in many control groups with metho-
trexate.
Figure 1 shows a meta-analysis to compare treatment
differences for the proportions of patients who met ACR50
versus their counterparts meeting ACR20 through the most
significant difference of differences for each trial. Overall, 12
reports indicated greater differences between active and
Figure 1 Meta-analysis of ACR50 versus ACR20 differences for proportions of patients meeting each end point with active versus control treatments in
21 clinical trials. The treatment comparison with the difference of differences that is most significantly different from zero is shown for each trial. The
Hodges–Lehmann confidence interval (CI) from an analysis of combined studies shows that the median difference of differences is not significantly
different from zero, showing no major advantage of ACR20 or ACR50. ABAT, abatacept; ADA, adalimumab; ANAK, anakinra; CYCLO, cyclosporine;
DMARD, disease-modifying antirheumatic drug; ETAN, etanercept; HCQ, hydroxychloroquine; INFL, infliximab; LEF, leflunomide; MTX, methotrexate;
PBO, placebo; PRED, prednisone; RTX, rituximab; SSZ, sulphasalazine; TAC, tacrolimus.
1604 Chung, Thompson, Koch, et al
www.annrheumdis.com
control treatments according to ACR20 versus ACR50 criteria,
four of which were significant. Four reports indicated
virtually identical results according to both response criteria
and five reports indicated a larger treatment difference of
response according to ACR50 compared to ACR20 criteria;
two of these differences were significant (fig 1). The meta-
analysis comparison of all studies indicated a slight advan-
tage to ACR20, although the Hodges–Lehmann 95% CI for
ACR50 versus ACR20 included the zero point, indicating that
it was not significant (fig 1).
In a meta-analysis of ACR50 versus ACR20 according to
the most significant ratio of active versus control ORs for
each trial, CIs in general were much wider than their
counterparts for differences of differences (fig 2). Overall,
seven studies favoured ACR20, generally the same studies
with this result for differences between proportions, although
none were significant in an OR analysis. By contrast, 14
studies favoured ACR50, three of which were significant. The
Hodges–Lehmann 95% CI for this meta-analysis indicated a
significant (although small) advantage to ACR50 versus
ACR20 responses according to ORs (fig 2).
DISCUSSION
These data confirm the validity of ACR20 as an optimal
discriminator to distinguish active versus control treatment
in clinical trials conducted before 1997, in agreement with
the published report.5 In trials conducted since 1997,
however, results according to ACR50 seem similar to those
according to ACR20. In the meta-analyses, treatment
differences for ACR50 proportions did not differ significantly
from their ACR20 counterparts, whereas ratios of ORs slightly
favoured ACR50, with a significant advantage. Both types of
meta-analysis indicated agreement in most clinical trials,
although point estimates in 7 of the 21 trials in table 1 differ
in the end point they favour according to the two methods.
However, the 95% CIs overlap the value for no difference in
all but one of these cases in both figures, illustrating both the
value of CIs in accounting for the random variability of point
estimates and the possible value of analysing the discrimi-
nant capacity of the two end points using two different
methods.
As noted in the Methods section, the meta-analysis
reported here is in some ways similar to a traditional meta-
analysis, as it integrates findings in many clinical trials into
one quantitative analysis. However, the goal in our studies
was to compare discriminant capacities of results reported
according to ACR20 and ACR50 criteria to detect differences
between active and control treatments, rather than to analyse
the efficacy of a particular treatment versus a control in many
different clinical trials. Furthermore, this review was directed
to compare responses reported as ACR20 versus ACR50, as
described in the medical literature, without any comment on
the implications regarding the treatments under study.
These considerations led us to not deal with matters that
might be included in a meta-analysis on a given treatment,
such as differences in patient populations, duration of
studies, methods to account for missing data, or doses of
methotrexate or no methotrexate in a control group. Any
Figure 2 Meta-analysis of ACR50 versus ACR20 ratios of odds ratios (OR) for meeting each end point with active versus control treatments in 21
clinical trials. The treatment comparison for which the logarithm of the ratio of ratios is most significantly different from zero is shown for each trial. The
Hodges–Lehmann confidence interval (CI) from the analysis of the combined studies shows that the median ratio of ORs is significantly .1, indicating a
slight advantage of ACR50 compared with ACR20. ABAT, abatacept; ADA, adalimumab; ANAK, anakinra; CYCLO, cyclosporine; DMARD, disease-
modifying antirheumatic drug; ETAN, etanercept; HCQ, hydroxychloroquine; INFL, infliximab; LEF, leflunomide; MTX, methotrexate; PBO, placebo;
PRED, prednisone; RTX, rituximab; SSZ, sulphasalazine; TAC, tacrolimus.
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influence of these matters on results is arguably similar for
ACR20 and ACR50 in each trial, and thereby seems minimal
for a comparison of these two criteria. Moreover, hetero-
geneity among trials was managed as random variability,
using the methods for obtaining overall results. Further
analyses may provide additional information on the optimal
methods to assess clinical responses in trials on rheumatoid
arthritis, but could require access to the original data, which
were not available to the authors. Other approaches to
analysing comparisons between active versus control treat-
ments in clinical trials on rheumatoid arthritis, including the
Disease Activity Score42 and indices that include only patient
measures,43 were also not dealt with here.
The meta-analysis of 21 clinical trials conducted on
patients with rheumatoid arthritis since 1997 indicated
similar discriminant capacities of ACR20 and ACR50
responses. The evidence that active versus control treatments
can be distinguished according to ACR50, and according to
ACR20, seems to attest the superiority of newer therapeutic
approaches and agents versus those reported before 1998. The
effective discriminant capacity of ACR50 versus ACR20 was
as likely in trials on early and aggressive combinations of
DMARDs as in trials on biological agents, suggesting that an
aggressive approach may be as important as a specific new
agent in improving outcomes in rheumatoid arthritis. Further
analyses using different methods of calculating responses
will contribute to improved methods to analyse comparisons
between active and control treatments in clinical trials on
rheumatoid arthritis. On the basis of the meta-analyses
reported here, it seems reasonable to conclude that ACR50
may be a preferred end point, as it is a considerably more
desirable target for people who have rheumatoid arthritis.
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